Integrated multi-dimensional analyses reveal a BTN3A2-centered diagnostic risk score and a monocyte-T cell axis as central drivers of dermatomyositis
An 18-gene blood signature accurately identifies dermatomyositis patients, offering a faster, less invasive diagnostic path than current clinical approaches.
This multi-omics study of dermatomyositis constructed and externally validated an 18-gene diagnostic risk score (AUC 0.957 discovery / 0.724 external validation) centered on BTN3A2 as a causally relevant hub gene identified through Mendelian randomization. Single-cell RNA sequencing revealed that CD14+/CD16+ monocytes and T-cell subsets drive the risk signature via LGALS9-CD44/CD45 intercellular signaling.
What the study was
- Study design
- Multi-omics observational study (bulk transcriptomics, SMR Mendelian randomization, scRNA-seq)
- Population
- Dermatomyositis patients (multi-dataset, public databases)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Clinical Rheumatology
Why it surfaced
Methodologically interesting multi-omics diagnostic risk model for dermatomyositis (DM) with external validation. Outside the primary watchlist (rheumatology, not oncology/hematology/cardiometabolic). Score 5 warrants STANDARD tagging but pipeline_ready false given out-of-scope disease area.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.